title: Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery.
abstract: This study was to develop a thiolated non-ionic surfactant, cysteine-polyethylene glycol stearate (Cys-PEG-SA), for the assembling of nanoparticulate ocular drug delivery system with mucoadhesive property. Cys-PEG-SA was synthesized in two steps reaction involving a new derivative intermediate formation of p-nitrophenylcarbonyl-PEG-SA (pNP-PEG-SA). Up to 369.43+/-25.54 mumol free thiol groups per gram of the conjugates was reached. The nanostructured lipid carrier (NLC) loaded cyclosporine A (CyA) was prepared by melt-emulsification method. The mucoadhesive NLC (Cys-NLC) was obtained by incubating NLC emulsion with Cys-PEG-SA. The mucoadhesive properties of these nanocarriers were examined by using mucin particles method. The particle size or zeta potential of the porcine mucin particles were changed with the added concentration of Cys-PEG-SA, and the disulphide bond breaker cysteine significantly reduced the adhesion of Cys-NLC to mucin particles (P<0.05), whereas PEG-SA and NLC did not alternate the properties of the mucin particles. When Cys-NLC was administered topically to the rabbit eye, the encapsulated cyclosporine was found to remain on the ocular surface in the cul-de-sac for up to 6 h, both precorneal retention time and concentration were dramatically increased (P<0.05), compared with the NLC without thiomer modification.
authors.affiliation: School of Pharmacy, China Pharmaceutical University, Nanjing-210009, PR China.
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Qineng
authors.initials: Q
authors.lastname: Ping
authors.forename: Yanyu
authors.initials: Y
authors.lastname: Xiao
authors.forename: Xin
authors.initials: X
authors.lastname: Huang
mesh_terms: D000268:Adhesiveness; D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics*; D003545:Cysteine / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry; D008297:Male; D009077:Mucins / Q000737:chemistry; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D010316:Particle Size; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry*; D011817:Rabbits; D013438:Sulfhydryl Compounds / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry*; D013552:Swine; D013666:Tears / Q000378:metabolism; D014783:Viscosity
chemical_list: D008055:Lipids; D009077:Mucins; D009883:Ophthalmic Solutions; D013438:Sulfhydryl Compounds; D011092:Polyethylene Glycols; D016572:Cyclosporine; C009314:polyethylene glycol monostearate; D003545:Cysteine